PEN250117P130000
- 5.00
- 0.000.00%
Penumbra Newsroom
Here's Why Penumbra (PEN) Is a Strong Growth Stock
RBC Capital Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $285
10 Health Care Stocks With Whale Alerts In Today's Session
Penumbra Is Maintained at Buy by Truist Securities
Truist Securities Adjusts Price Target on Penumbra to $285 From $240, Keeps Buy Rating
Truist Financial Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $285
Express News | Penumbra Inc : RBC Raises Target Price to $285 From $232
Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst
Oppenheimer Maintains Penumbra(PEN.US) With Buy Rating, Maintains Target Price $275
This Elastic Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Penumbra Initiated at Outperform by Oppenheimer
Oppenheimer Initiates Penumbra(PEN.US) With Buy Rating, Announces Target Price $275
3 Medical Instruments Industry Stocks to Buy on the GenAI Wave
Top Gap Ups and Downs on Wednesday: MLI, MSTR, GSK and More
Price Over Earnings Overview: Penumbra
Penumbra Shares Are Trading Higher After Wells Fargo Upgraded the Stock From Equal-Weight to Overweight and Raised Its Price Target From $190 to $275.
12 Analysts Assess Penumbra: What You Need To Know
Citi Maintains Penumbra(PEN.US) With Hold Rating, Raises Target Price to $245
Wells Fargo Upgrades Penumbra to Overweight From Equalweight, Price Target Is $190
Penumbra Price Target Raised to $245 From $220 at Citi